|
Apr 24
|
Those who invested in Imugene (ASX:IMU) five years ago are up 361%
|
|
Dec 6
|
Imugene to commence new phase 2 PD1-Vaxx bowel cancer trial
|
|
Nov 28
|
Imugene thrilled as VAXINIA granted FDA Fast Track designation
|
|
Nov 6
|
Imugene sees positive early signals in Phase 1 VAXINIA study
|
|
Jun 28
|
Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
|